|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
BEFREE |
For example, plasminogen-dependent and - independent effects of tPA and uPA play a central role in the pathophysiological events that underlie one of the leading causes of mortality and disability in the world: cerebral ischemia.
|
30539695 |
2019 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
BEFREE |
We sought to determine whether patients with stroke with an unknown time of onset and features suggesting recent cerebral infarction on magnetic resonance imaging (MRI) would benefit from thrombolysis with the use of intravenous alteplase.
|
29766770 |
2018 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
BEFREE |
Compared with the rt-PA and rPA groups, total cholesterol (TC), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were lower, whereas the hematocrit, whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity, erythrocyte electrophoresis time, fibrinogen, erythrocyte sedimentation rate (ESR), <i>K</i> value in blood sedimentation equation, and the comprehensive abnormality degree of blood rheology were higher in the rt-PA + aspirin and rPA + aspirin groups.<b>Conclusion:</b> The efficacy and safety of rt-PA or rPA combined with aspirin in the treatment of hyper-acute CI were better than those of rPA or rt-PA monotherapy.
|
29263145 |
2018 |
|
Cerebral Infarction
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Cerebral ischemia causes the presynaptic release of tissue-type plasminogen activator (tPA).
|
29547062 |
2018 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
BEFREE |
An intravenous recombinant tissue plasminogen activator (rt-PA, alteplase .6 mg/kg) for acute cerebral infarction within 3 hours of onset was approved in Japan in 2005.
|
29221968 |
2018 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
BEFREE |
Early reperfusion with tissue-type plasminogen activator (tPA) is an effective therapeutic strategy to treat acute ischemic stroke, but only 1/3 of tPA-treated patients recover and are free from disability. tPA has also shown neurotoxicity in experimental models of cerebral ischemia.
|
28379489 |
2017 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
BEFREE |
The overall effective rates of intra-arterial thrombolysis in treating the acute cerebral infarction by reteplase had no significant differences compared to those by rt-PA, and there were no hemorrhagic complications.
|
27352315 |
2015 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
CTD_human |
The application of fast multiparametric protocol MRI-based thrombolysis with rt-PA hyperacute cerebral infarction.
|
18544249 |
2008 |
|
Cerebral Infarction
|
0.390 |
Therapeutic
|
disease |
CTD_human |
The application of fast multiparametric protocol MRI-based thrombolysis with rt-PA hyperacute cerebral infarction.
|
18544249 |
2008 |
|
Cerebral Infarction
|
0.390 |
Therapeutic
|
disease |
CTD_human |
Homonymous hemianopia caused by occipital lobe infarction in heparin-induced thrombocytopenia and thrombosis syndrome.
|
16148626 |
2005 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
CTD_human |
Homonymous hemianopia caused by occipital lobe infarction in heparin-induced thrombocytopenia and thrombosis syndrome.
|
16148626 |
2005 |
|
Cerebral Infarction
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
However, tPA is also expressed within the CNS where it has a very different function, promoting events associated not only with synaptic plasticity but also with cell death in a number of settings, such as cerebral ischemia and seizures.
|
14983220 |
2004 |
|
Cerebral Infarction
|
0.390 |
Therapeutic
|
disease |
CTD_human |
Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke.
|
15502123 |
2004 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
CTD_human |
Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke.
|
15502123 |
2004 |
|
Cerebral Infarction
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
In this study we demonstrate that an increase in endogenous tissue-type plasminogen activator (tPA) activity in the perivascular tissue following cerebral ischemia induces opening of the BBB via a mechanism that is independent of both plasminogen (Plg) and MMP-9.
|
14617754 |
2003 |
|
Cerebral Infarction
|
0.390 |
Therapeutic
|
disease |
CTD_human |
Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II pilot and randomized clinical trial combined experience.
|
9183334 |
1997 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
CTD_human |
Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II pilot and randomized clinical trial combined experience.
|
9183334 |
1997 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
CTD_human |
Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke.
|
1579960 |
1992 |
|
Cerebral Infarction
|
0.390 |
Therapeutic
|
disease |
CTD_human |
Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke.
|
1579960 |
1992 |
|
Cerebral Infarction
|
0.390 |
Therapeutic
|
disease |
CTD_human |
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
|
1899364 |
1991 |
|
Cerebral Infarction
|
0.390 |
Biomarker
|
disease |
CTD_human |
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
|
1899364 |
1991 |